Company

Giorgio has a Chemist Degree cum Laude at the University of Modena. Researcher in fiber surface treatments for textile industry @SNIA spa (Italy), then hospital chemist assistant in the clinical chemistry laboratory.

In 1980 Quality Manager then production and research Director @Miramed Srl, sold to Baxter 1984. In 1990 Founder of Biofil srl, acting as Production and Research Director for the development of blood filters. Biofil srl was sold to Fresenius AG in 1993, and Giorgio became CEO first then administrator and member of the board of Fresenius HemoCare Italia Srl, part of the Fresenius SE (Germany).

In 2017, after more than 20 years of management in a large multinational company, he became CEO and member of the board of Rigenerand srl responsible for the research on medical devices and the cell factory for the production of advanced cell and gene therapies.

Massimo has a MD degree cum laude at University of Pavia and a Post-graduate internship at the Vienna University; residency cum laude in Hematology at University of Ferrara and Post-Doctoral Associate at St. Jude Children Hospital in Memphis (USA).

He is now Full Professor of Oncology, Director of the Oncology Division and of the Residency School in Oncology at the University Hospital of Modena and Reggio Emilia (Modena). Since 2005 he is heading the Laboratory of Cellular Therapies with over 25 Mio € in research grants, > 300 papers, > 58000 citations and H-index of 68 (G. Scholar), 15 patents. More than 300 invited lectures.

Founder of the university start-up Rigenerand srl, sold to Evotec SE For 24 Mio € in July 2022. He has been President of the International Society of Cell and Gene Therapy (ISCT) 2014-2016.